ALNYLAM PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 2.60% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2020-02-13
- ALNYLAM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.60%, a 10.34% decline from fiscal 2018.
- ALNYLAM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 2.90%, a 26.09% increase from fiscal 2017.
- ALNYLAM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.30%, a 4.55% increase from fiscal 2016.
- ALNYLAM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 2.20%, a 10.00% increase from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2019-12-31 | 2.60% 10-K · filed 2020-02-13 |
| 2018-12-31 | 2.90% 10-K · filed 2020-02-13 |
| 2017-12-31 | 2.30% 10-K · filed 2020-02-13 |
| 2016-12-31 | 2.20% 10-K · filed 2019-02-14 |
| 2015-12-31 | 2.00% 10-K · filed 2018-02-15 |
| 2014-12-31 | 2.30% 10-K · filed 2017-02-15 |
| 2013-12-31 | 2.00% 10-K · filed 2016-02-12 |
| 2012-12-31 | 1.00% 10-K · filed 2015-02-13 |
| 2011-12-31 | 2.60% 10-K · filed 2014-02-20 |
| 2010-12-31 | 2.90% 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |